

Personalized Medicine Options for Depression

RXMATCH™ ANTIDEPRESSANT PANEL



WHY PGx FOR DEPRESSION?

Pharmacogenomics, or PGx, is the study of how genes affect a patient's response to medications. Precision Genomics RxMatch™ Antidepressant Panel (a DNA test) is an approach to applying PGx insights to treating depression faster and more effectively. Intermountain Precision Genomics is partnering with CNSDose to deliver this new service.

Using genetically guided treatments, physicians can fast-track finding the right medication and dose for patients suffering from depression. Until now, trial and error prescribing could take months (sometimes years) to find the right drug and dose.



OUR PROCESS



OBTAIN COLLECTION KIT

1. Visit www.Intermountain.com/RxMatch
2. Click "Request Provider Account" or call 435.251.5780 to request a Starter Kit with 10 specimen collection kits (more upon request).
3. An account representative will contact your office for training and to answer any questions.



ORDER, COLLECT, & SEND

1. Fill out RxMatch Order Form (included in starter kit).
2. Collect DNA sample from gum-line, being careful not to touch teeth or tongue.
3. Send patient sample, order form and insurance information via Intermountain Courier Services 801.442.4090.



REPORT

Physicians receive an email within a week to access the report. Use the report to guide decisions on medication and recommended dosage based on a patient's DNA.



WHO WE ARE & WHAT WE DO

Working at the forefront of medical science and technology, Intermountain Precision Genomics, based in St. George, UT, leverages the power of next-generation sequencing and state-of-the-art genomic technology to enable translational research. We are a dedicated group inside Intermountain Healthcare composed of scientists, physicians and technicians under visionary leadership, fueled by a passion to deliver on the promise of personalized treatments to improve patients' lives.

BATTLING DEPRESSION IS NOW PERSONAL




HOW IT WORKS

PGx testing identifies how quickly (or slowly) a patient metabolizes medication. Specifically, RxMatch™ considers how the liver and brain process medications. The Precision Genomics Antidepressant panel, powered by CNSDose reporting system, is backed by published clinical evidence.

END TRIAL & ERROR PRESCRIBING

Data shows 30-50% of depressed patients do not respond to their first medication, leaving physicians to resort to time-consuming trial and error to find the right solution. By applying a genetic approach, physicians can more quickly pinpoint the right prescription.

- The average patient spends over \$5000 per year trying to find the right prescription and dose
- 66% of patients who stopped taking medication within 60 days cited problematic side effects
- 42% of patients discontinue use after 12 weeks
- Researchers found genetically guided treatments resulted in 72% full symptom recovery for patients vs. 28% using unguided prescribing (250% better than trial and error).



UNGUIDED PRESCRIBING



GUIDED PRESCRIBING



SIMPLE, FAST, PERSONALIZED RESULTS

Once analysis is complete, the physician receives an easy to use CNSDose Report providing guidance on appropriate medication and dosing suggestions.

